Authorized COVID Antiviral Fails to Cut Hospitalization Risk
Molnupiravir failed to reduce the risk for hospitalization or death in high-risk COVID-19 outpatients who took the oral antiviral within 5 days of symptoms, a large open-label multicenter trial found.
Tuesday, October 11, 2022 at 9:31 pm